1. Executive Summary (Confidence: High)

Tolremo Therapeutics addresses one of the most critical challenges in oncology: the nearly universal emergence of drug resistance that leads to patient relapse.^[18] Founded in 2017 as a spin-off from ETH Zürich, the company pioneered the understanding of "transcriptional non-oncogene addiction"—a process where cancer cells shift their gene expression patterns to survive initial treatment without the immediate need for new genetic mutations.^[18] By identifying and targeting the early, reversible steps of resistance, Tolremo aims to make current cancer treatments work longer and more effectively.^[20]

The organization’s flagship asset, TT125-802, is a selective inhibitor of the CBP/p300 bromodomain, a master regulator of the gene expression changes that drive therapy evasion.^[18] Following a successful USD 39 million Series A round in 2023, the company has transitioned into clinical development, dosing the first patient in a Phase 1 trial in mid-2024.21 Tolremo's business strategy centers on "add-on" combination therapies, positioning its technology as a essential companion to blockbuster targeted drugs like KRAS and EGFR inhibitors in large-market indications such as lung, colorectal, and prostate cancer.^[18]